Edwards Lifesciences (EW) Change in Accured Expenses (2009 - 2026)

Edwards Lifesciences has reported Change in Accured Expenses for 18 years, with the latest figure at -$347.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 235.69% year-over-year to -$347.1 million; the trailing twelve-month figure through Mar 2026 stood at $151.4 million (up 101.33% YoY), and the FY2025 full-year result was $395.1 million, up 341.45% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$347.1 million, down from $168.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $226.1 million in Q3 2025, with the low at -$347.1 million in Q1 2026.
• Average Change in Accured Expenses over 5 years is $15.4 million, with a median of $29.9 million recorded in 2024.
• Year-over-year, Change in Accured Expenses slumped 1074.19% in 2022 and jumped 5541.94% in 2025.
• Tracing EW's Change in Accured Expenses over 5 years: stood at $34.3 million in 2022, then decreased by 2.62% to $33.4 million in 2023, then sank by 109.28% to -$3.1 million in 2024, then jumped by 5541.94% to $168.7 million in 2025, then plunged by 305.75% to -$347.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$347.1 million (Q1 2026), $168.7 million (Q4 2025), and $226.1 million (Q3 2025), per Business Quant data.

Peer Comparison